Study: NCT01010217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months